Simpa S Salami1, Jeffrey J Tosoian2, Srinivas Nallandhighal3, Tonye A Jones4, Scott Brockman3, Fuad F Elkhoury4, Selena Bazzi3, Komal R Plouffe5, Javed Siddiqui6, Chia-Jen Liu6, Lakshmi P Kunju5, Todd M Morgan7, Shyam Natarajan4, Philip S Boonstra8, Lauren Sumida9, Scott A Tomlins10, Aaron M Udager11, Anthony E Sisk9, Leonard S Marks4, Ganesh S Palapattu12. 1. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA. Electronic address: simpa@med.umich.edu. 2. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA. 3. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA. 4. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 5. Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA. 6. Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA. 7. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. 8. Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. 9. Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 10. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA. 11. University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA. 12. Department of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Urology, Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p < 0.001), and RNAseq-based fusion and isoform expression were concordant in nine of 13 (69%) ERG+ patients, supporting focal resampling. Among 15 men who upgraded with complete data at both time points, integrated DNA/RNAseq analysis provided evidence of shared clonality in at least five cases. Such cases could reflect initial undersampling, but also support the possibility of clonal temporal progression of low-grade cancer. Our assessment was limited by sample size and use of targeted sequencing. CONCLUSIONS: Repeat molecular assessment of low-grade tumors suggests that clonal progression could be one mechanism of upgrading. These data underscore the importance of serial tumor assessment in men pursuing AS of low-grade PCa. PATIENT SUMMARY: We performed targeted rebiopsy and molecular testing of low-grade tumors on active surveillance. Our findings highlight the importance of periodic biopsy as a component of monitoring for cancer upgrading during surveillance.
BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p < 0.001), and RNAseq-based fusion and isoform expression were concordant in nine of 13 (69%) ERG+ patients, supporting focal resampling. Among 15 men who upgraded with complete data at both time points, integrated DNA/RNAseq analysis provided evidence of shared clonality in at least five cases. Such cases could reflect initial undersampling, but also support the possibility of clonal temporal progression of low-grade cancer. Our assessment was limited by sample size and use of targeted sequencing. CONCLUSIONS: Repeat molecular assessment of low-grade tumors suggests that clonal progression could be one mechanism of upgrading. These data underscore the importance of serial tumor assessment in men pursuing AS of low-grade PCa. PATIENT SUMMARY: We performed targeted rebiopsy and molecular testing of low-grade tumors on active surveillance. Our findings highlight the importance of periodic biopsy as a component of monitoring for cancer upgrading during surveillance.
Authors: Paul R Womble; James E Montie; Zaojun Ye; Susan M Linsell; Brian R Lane; David C Miller Journal: Eur Urol Date: 2014-08-24 Impact factor: 20.096
Authors: Rohit Mehra; Bo Han; Scott A Tomlins; Lei Wang; Anjana Menon; Matthew J Wasco; Ronglai Shen; James E Montie; Arul M Chinnaiyan; Rajal B Shah Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701
Authors: Christopher Warlick; Bruce J Trock; Patricia Landis; Jonathan I Epstein; H Ballentine Carter Journal: J Natl Cancer Inst Date: 2006-03-01 Impact factor: 13.506
Authors: Ganesh S Palapattu; Simpa S Salami; Andi K Cani; Daniel H Hovelson; Lorena Lazo de la Vega; Kelly R Vandenberg; Jarred V Bratley; Chia-Jen Liu; Lakshmi P Kunju; Jeffery S Montgomery; Todd M Morgan; Shyam Natarajan; Jiaoti Huang; Scott A Tomlins; Leonard S Marks Journal: Clin Cancer Res Date: 2016-10-07 Impact factor: 12.531
Authors: Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju Journal: Arch Pathol Lab Med Date: 2012-08 Impact factor: 5.534
Authors: Lei Wei; Jianmin Wang; Erika Lampert; Simon Schlanger; Adam D DePriest; Qiang Hu; Eduardo Cortes Gomez; Mitsuko Murakam; Sean T Glenn; Jeffrey Conroy; Carl Morrison; Gissou Azabdaftari; James L Mohler; Song Liu; Hannelore V Heemers Journal: Eur Urol Date: 2016-07-21 Impact factor: 20.096
Authors: Kathryn L Penney; Meir J Stampfer; Jaquelyn L Jahn; Jennifer A Sinnott; Richard Flavin; Jennifer R Rider; Stephen Finn; Edward Giovannucci; Howard D Sesso; Massimo Loda; Lorelei A Mucci; Michelangelo Fiorentino Journal: Cancer Res Date: 2013-08-15 Impact factor: 12.701
Authors: Daniel H Hovelson; Andrew S McDaniel; Andi K Cani; Bryan Johnson; Kate Rhodes; Paul D Williams; Santhoshi Bandla; Geoffrey Bien; Paul Choppa; Fiona Hyland; Rajesh Gottimukkala; Guoying Liu; Manimozhi Manivannan; Jeoffrey Schageman; Efren Ballesteros-Villagrana; Catherine S Grasso; Michael J Quist; Venkata Yadati; Anmol Amin; Javed Siddiqui; Bryan L Betz; Karen E Knudsen; Kathleen A Cooney; Felix Y Feng; Michael H Roh; Peter S Nelson; Chia-Jen Liu; David G Beer; Peter Wyngaard; Arul M Chinnaiyan; Seth Sadis; Daniel R Rhodes; Scott A Tomlins Journal: Neoplasia Date: 2015-04 Impact factor: 5.715
Authors: Benjamin H Press; Tashzna Jones; Olamide Olawoyin; Soum D Lokeshwar; Syed N Rahman; Ghazal Khajir; Daniel W Lin; Matthew R Cooperberg; Stacy Loeb; Burcu F Darst; Yingye Zheng; Ronald C Chen; John S Witte; Tyler M Seibert; William J Catalona; Michael S Leapman; Preston C Sprenkle Journal: Eur Urol Open Sci Date: 2022-02-11